Emoksibel - instructions for use, reviews, analogs and forms of release (injections in ampoules for injections and infusions in solution, eye drops 1%) for the treatment of heart attack, stroke, eye diseases in adults, children and pregnancy. Composition

In this article, you can read the instructions for using the drug Emoxibel. Presented are reviews of visitors to the site - consumers of this medication, as well as opinions of doctors specialists on the use of Emoxibel in their practice. A big request is to actively add their feedback on the drug: the medicine helped or did not help get rid of the disease, which were observed complications and side effects, possibly not declared by the manufacturer in the annotation. Analogs of Emoxibel in the presence of existing structural analogs.Use for the treatment of heart attack, stroke, eye diseases in adults, children, as well as during pregnancy and lactation. Composition of the preparation.

Emoxibel - is an inhibitor of free radical processes, an antihypoxant and an antioxidant. Reduces blood viscosity and platelet aggregation, increases the content of cyclic nucleotides in platelets and brain tissue, has fibrinolytic activity, reduces the permeability of the vascular wall and the risk of developing hemorrhages, contributes to their resorption. Expands coronary vessels, in the acute period of myocardial infarction limits the magnitude of the focus of necrosis, improves the contractility of the heart and the function of its conductive system.

At the raised arterial pressure (BP) has an antihypertensive effect. In acute ischemic impairment of cerebral circulation reduces the severity of neurologic symptoms, increases tissue resistance to hypoxia and ischemia. Also, methylethylpyridinol (the active substance of the drug Emoxibel), having retinoprotective action, protects the retina from the damaging effect of high-intensity light.Promotes resorption of intraocular hemorrhages, reduces blood clotting, improves microcirculation of the eye. Stimulates reparative processes in the cornea (including in the early postoperative and post-natal period).

Composition

Methyl ethylpyridinol hydrochloride (emoxipine) + excipients.

Pharmacokinetics

Quickly penetrates into the organs and tissues, where it is deposited and metabolized. In the tissues of the eye, the concentration is higher than in the blood. Metabolised in the liver. In significant quantities, an active metabolite of 2-ethyl-6-methyl-3-hydroxypyridine phosphate is found in the liver. Further in the blood under the influence of alkaline phosphatase there is a splitting of 2-ethyl-6-methyl-3-hydroxypyridinaphosphate into phosphoric acid and 3-hydroxypyridine. Metabolites are excreted by the kidneys.

Indications

In neurology and neurosurgery:

• hemorrhagic stroke;
• ischemic stroke in the basin of the internal carotid artery and in the vertebrobasilar system;
• transient disorders of cerebral circulation;
• chronic cerebral circulatory failure;
• craniocerebral injury, accompanied by bruises of the brain;
• postoperative period in patients with craniocerebral trauma, operated on the epidural, subdural and intracerebral hematomas, combined with bruises of the brain.

In cardiology:

• acute myocardial infarction;
• prevention of "reperfusion syndrome";
• unstable angina.

In ophthalmology:

• subconjunctival and intraocular hemorrhages of different genesis;
• angioretinopathy (including diabetic retinopathy);
• central and peripheral chorioretinal dystrophy;
• thrombosis of the central vein of the retina and its branches;
• complicated myopia;
• angiosclerotic macular degeneration (dry form);
• otloyka of the choroid of the eye in patients with glaucoma in the postoperative period;
• dystrophic diseases of the cornea;
• trauma, burns of the cornea;
• treatment and prevention of damage to the tissues of the eye with high intensity light (sun rays, laser radiation with laser coagulation);
• complications with myopia (treatment);
• protection of the cornea (when wearing contact lenses).

Forms of release

Injections in ampoules for injection in a solution of 5 ml.

Injections in ampoules for infusions of 100 ml.

Eye drops 1% 5 ml.

Solution for intraocular administration 1 ml.

Instructions for use and dosing regimen

In cardiology and neurology, intravenously or intramuscularly

The dose, the duration of the course of treatment is determined individually. For intravenous administration, the preparation is previously diluted in 200 ml of a 0.9% solution of sodium chloride or a 5% solution of dextrose.

In neurology and neurosurgery: intravenously drip at a rate of 20-30 drops per minute at a dose of 10 mg per kilogram per day for 10-12 days, then switch to intramuscular injection of 60-300 mg 2-3 times a day for 20 days .

In cardiology: intravenously drip at a rate of 20-40 drops per minute at a dose of 600-900 mg 1-3 times a day for 5-15 days, followed by a transition to intramuscular injection of 60-300 mg 2-3 times daily for 10 -30 days.

In ophthalmology

Drops are instilled in the conjunctival sac 1-2 drops 2-3 times a day. The duration of the course of treatment depends on the course of the disease (usually 3-30 days) and is determined by the doctor. In the presence of indications and good tolerability, the duration of treatment can be up to 6 months. Repeated courses of treatment can be conducted 2-3 times a year.

Subconjunctival, parabulbar. If necessary, retrobulbar injection is possible.

Subconjunctivally enter 0.2-0.5 ml (2-5 mg), parabulbarno 0.5-1 ml (5-10 mg) of a 1% solution. The drug is used for 10-30 days once a day or every other day. If necessary, treatment can be repeated 2-3 times a year.

Retrobulbarno inject 0.5-1 ml of the drug for 10-15 days 1 time per day.

To protect the retina in laser coagulation (especially laser coagulation, which limits or destroys the tumor), 0.5-1 ml of Emoxibel is injected parabulbar or retrobulbarno 24 and 1 hour before the procedure and then for 2-10 days 1 time per day.

Side effect

• at intravenous introduction - sensation of a burning sensation on a course of a vein;
• increased blood pressure, excitation (short-term), or drowsiness;
• headache;
• pain in the heart;
• nausea;
• discomfort in the epigastric region;
• itching and redness of the skin;
• allergic reactions;
• burning sensation, itching in the eye;
• short-term congestion hyperemia.

Contraindications

• increased individual sensitivity to emoxipin;
• pregnancy, lactation;
• children under 18 years.

Carefully

Patients with hemostasis disorder, during surgical operations or patients with symptoms of severe bleeding (due to the effect on platelet aggregation).

Application in pregnancy and lactation

Emoxibel is contraindicated in pregnancy and lactation.

Use in children

Use of Emoxibel is contraindicated in children and adolescents under the age of 18 years.

special instructions

It is necessary during the treatment to constantly monitor blood pressure and clotting of blood.

Emoxibel solution for infusion is not recommended to be mixed with other drugs.

If it is necessary to simultaneously apply other eye drops, the drug should be instilled by the patient not earlier than 15 minutes after the complete absorption of the previous drug.

Impact on the ability to drive vehicles and manage mechanisms

Individuals who report drowsiness or a decrease in blood pressure after using Emoxibel should refrain from driving and potentially dangerous mechanisms.

Drug Interactions

Methyl ethylpyridinol is pharmaceutically incompatible with other drugs, so mixing in one syringe or infusomate with other injecting agents is not allowed.

Alpha-tocopherol acetate potentiates the antioxidant effect of Emoxibel.

Analogs of the drug Emoxibel

Structural analogs for the active substance:

• Vixipine;
• Cardiocipine;
• Methyl ethylpyridinol;
• Emotion Optics;
• Emoxipine.

Analogues on the pharmacological group (antihypoxants, antioxidants):

• Actovegin;
• Angiosyl;
• Antisthenes;
• Astrox;
• Valeocor-Q10;
• Vitanam;
• Hypoxen;
• Histochrome;
• Deprenorm;
• Dihydroquercetin;
• Dimephosphone;
• Cardiocipine;
• Carditrim;
• Carnitine;
• Carniffite;
• Confusamine;
• Laproth;
• Levocarnitine;
• Mexidol;
• Mexicor;
• Mexiprim;
• Metostabil;
• Mitomin;
• Neurocardia;
• Neurox;
• Oxyl;
• Octolipen;
• Oliphen;
• Predizin;
• Preductal;
• Precardard;
• Proxipin;
• Rexod;
• Romekor;
• Solcoseryl;
• Tridoukard;
• Trimectal;
• Trimetazidine;
• Cerekard;
• Cytochrome;
• Energet;
• Epigallocatechin;
• Ethoxydol;
• Echinochrome;
• Yantavit.

Recall of an ophthalmologist

Emoxibel is a highly effective drug for the treatment of eye diseases accompanied by hemorrhages of various origins. I prescribe drops and a solution for intraocular administration to patients with a hemorrhage in the sclera, in the anterior chamber of the eyes. Emoxibel is also effective for inflammation and burns of the cornea, for the treatment of complications with myopia. In addition, the drug is used to protect the cornea when using contact lenses, to protect the retina from the damaging effects of high-intensity light.

Similar medicines:

Other medicines: